HUP9902194A2 - Dibenzo-[b,f][1,4]tiazepin-származékot tartalmazó gyógyászati készítmények - Google Patents

Dibenzo-[b,f][1,4]tiazepin-származékot tartalmazó gyógyászati készítmények

Info

Publication number
HUP9902194A2
HUP9902194A2 HU9902194A HUP9902194A HUP9902194A2 HU P9902194 A2 HUP9902194 A2 HU P9902194A2 HU 9902194 A HU9902194 A HU 9902194A HU P9902194 A HUP9902194 A HU P9902194A HU P9902194 A2 HUP9902194 A2 HU P9902194A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
thiazepine derivative
containing dibenzo
dibenzo
Prior art date
Application number
HU9902194A
Other languages
English (en)
Inventor
William Joseph Addicks
Bhavnish Vinod Parikh
Robert Joseph Timko
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9902194(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of HUP9902194A2 publication Critical patent/HUP9902194A2/hu
Publication of HUP9902194A3 publication Critical patent/HUP9902194A3/hu
Publication of HU225152B1 publication Critical patent/HU225152B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A találmány tárgya nyújtőtt hatóanyag-felszabadűlású gyógyászatikészítmény, amely gélesítőszert és 11-[4-(2-/2-hidrőxi-etőxi/-etil)-1-piperazinil]-dibenző[b,f][1,4]tiazepint vagy gyógyászatilagalkalmazható sóját tartalmazza, egy vagy több gyógyászatilagalkalmazható excipienssel együtt. A gélesítőszer előnyösen hidrőxi-prőpil-metil-cellűlóz lehet. A készítmény pszichózis ellenes szerkéntvagy hiperaktivitás kezelésére alkalmazható. ŕ
HU9902194A 1996-05-31 1997-05-27 Pharmaceutical compositions containing dibenzo [b,f][1,4] thiazepine derivative HU225152B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9611328.7A GB9611328D0 (en) 1996-05-31 1996-05-31 Pharmaceutical compositions
PCT/GB1997/001432 WO1997045124A1 (en) 1996-05-31 1997-05-27 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
HUP9902194A2 true HUP9902194A2 (hu) 2000-02-28
HUP9902194A3 HUP9902194A3 (en) 2000-03-28
HU225152B1 HU225152B1 (en) 2006-07-28

Family

ID=10794541

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902194A HU225152B1 (en) 1996-05-31 1997-05-27 Pharmaceutical compositions containing dibenzo [b,f][1,4] thiazepine derivative

Country Status (31)

Country Link
EP (1) EP0907364B1 (hu)
JP (5) JP2000511170A (hu)
CN (3) CN1511532A (hu)
AR (1) AR003662A1 (hu)
AT (1) ATE222105T1 (hu)
AU (1) AU727219B2 (hu)
BR (1) BR9709271A (hu)
CA (1) CA2251944C (hu)
CZ (1) CZ293760B6 (hu)
DE (1) DE69714739T2 (hu)
DK (1) DK0907364T3 (hu)
EG (1) EG24118A (hu)
ES (1) ES2182079T3 (hu)
GB (2) GB9611328D0 (hu)
HR (1) HRP970299B1 (hu)
HU (1) HU225152B1 (hu)
ID (1) ID18352A (hu)
IL (1) IL127222A (hu)
MY (1) MY120120A (hu)
NO (1) NO327801B1 (hu)
NZ (1) NZ332198A (hu)
PL (1) PL189887B1 (hu)
PT (1) PT907364E (hu)
RU (1) RU2201754C2 (hu)
SI (1) SI0907364T1 (hu)
SK (1) SK284131B6 (hu)
TR (1) TR199802483T2 (hu)
TW (1) TW550076B (hu)
UA (1) UA50772C2 (hu)
WO (1) WO1997045124A1 (hu)
ZA (1) ZA974735B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050003001A1 (en) 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
EP1976487A2 (en) 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
PT1958617E (pt) 2007-02-14 2010-10-28 Lesvi Laboratorios Sl Composições farmacêuticas contendo fumarato de quetiapina
EP2131817A2 (en) 2007-03-09 2009-12-16 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
US20080287418A1 (en) * 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
US20110280938A1 (en) * 2009-01-05 2011-11-17 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
CN102218042A (zh) * 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
CN102406606B (zh) * 2011-11-29 2013-01-23 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
EP2822541B1 (en) 2012-09-10 2018-08-29 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
AU2016278846B2 (en) * 2015-06-19 2021-08-05 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN106187873B (zh) * 2016-07-25 2019-11-05 宜春学院 一种芳胺基烷基氧类化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
EP0266707B1 (en) * 1986-11-03 1992-01-22 Schering Corporation Sustained release labetalol tablet
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
JP3116970B2 (ja) * 1991-06-12 2000-12-11 三菱東京製薬株式会社 ペミロラストカリウムの徐放性製剤
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
WO1995031186A1 (en) * 1994-05-13 1995-11-23 Smithkline Beecham Corporation Method and composition for increasing calcium uptake

Also Published As

Publication number Publication date
SI0907364T1 (en) 2003-02-28
AU727219B2 (en) 2000-12-07
CA2251944A1 (en) 1997-12-04
HRP970299A2 (en) 1998-04-30
WO1997045124A1 (en) 1997-12-04
ID18352A (id) 1998-04-02
EG24118A (en) 2008-07-06
CZ388098A3 (cs) 1999-02-17
NZ332198A (en) 2000-05-26
GB9611328D0 (en) 1996-08-07
IL127222A0 (en) 2000-06-01
HU225152B1 (en) 2006-07-28
UA50772C2 (uk) 2002-11-15
JP2014167026A (ja) 2014-09-11
NO327801B1 (no) 2009-09-28
SK163998A3 (en) 1999-05-07
JP5888549B2 (ja) 2016-03-22
TR199802483T2 (xx) 1999-02-22
TW550076B (en) 2003-09-01
JP2006152006A (ja) 2006-06-15
DK0907364T3 (da) 2002-11-11
AU2967597A (en) 1998-01-05
BR9709271A (pt) 1999-08-10
CN101006985A (zh) 2007-08-01
JP2012031206A (ja) 2012-02-16
CA2251944C (en) 2007-04-10
CN1511532A (zh) 2004-07-14
EP0907364B1 (en) 2002-08-14
GB9709761D0 (en) 1997-07-09
ZA974735B (en) 1997-12-01
IL127222A (en) 2001-03-19
CZ293760B6 (cs) 2004-07-14
JP2000511170A (ja) 2000-08-29
DE69714739T2 (de) 2003-05-15
SK284131B6 (sk) 2004-09-08
MY120120A (en) 2005-09-30
PL189887B1 (pl) 2005-10-31
NO985539D0 (no) 1998-11-27
RU2201754C2 (ru) 2003-04-10
HUP9902194A3 (en) 2000-03-28
HRP970299B1 (en) 2001-12-31
PT907364E (pt) 2002-12-31
ATE222105T1 (de) 2002-08-15
JP2007119495A (ja) 2007-05-17
DE69714739D1 (de) 2002-09-19
CN1219879A (zh) 1999-06-16
EP0907364A1 (en) 1999-04-14
NO985539L (no) 1998-11-27
ES2182079T3 (es) 2003-03-01
PL330223A1 (en) 1999-05-10
CN1142780C (zh) 2004-03-24
AR003662A1 (es) 1998-09-09

Similar Documents

Publication Publication Date Title
HUP9902194A2 (hu) Dibenzo-[b,f][1,4]tiazepin-származékot tartalmazó gyógyászati készítmények
AU7052798A (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
AU7052698A (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
AU6132496A (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU6132596A (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU7578696A (en) Morpholine derivatives and their use as therapeutic agents
AU6517196A (en) Piperazine derivatives as therapeutic agents
AU5892396A (en) Jointless foot prosthesis
CA2304568A1 (en) Olanzapine pamoate formulations
TWI235068B (en) Sustained-release pharmaceutical composition
AU1573899A (en) Inflatable dental implant for receipt and support of a dental prosthesis
MY120999A (en) Crystalline dibenzothiazephine derivative and its use as an antipsychotic agent
AU3391395A (en) Morpholine derivatives and their use as therapeutic agents
AU7481996A (en) Vaginal pharmaceutical compositions containing a peroxide source
HUP0001494A3 (en) 3-phenoxy-, 3-dibenzo[a,d]cycloheptenyloxy-, 3-dibenz[b,f][1,4]oxazepinyloxy-1-amino-2-propanol derivatives and pharmaceutical compositions containing them
AU2679500A (en) Composition for freshening and deodorising textile materials
AU2003204896A1 (en) Anti-estrogen plus progestin containing oral contraceptives
AU8166098A (en) Removal of biologically active agents
AU1904197A (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route
FR2745500B1 (fr) Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
AU4100097A (en) Fluorescent whitening agent formulation
AU8400698A (en) Improved dissolution inhibition resists for microlithography
AU4813900A (en) Contraceptive compositions containing indoline derivatives and progestational agents
AU6940896A (en) 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2h)-one 1,1-dioxides and pharmaceutical compositions containing them
HU9602774D0 (en) Benzoxazepine derivatives, their salts and pharmaceutical compositions containing them